<scp>PERPRISE</scp>: A prospective non‐interventional study of <scp>PERampanel</scp> as only adjunctive treatment in patients with <scp>PRImary</scp> or <scp>SEcondarily</scp> generalized tonic–clonic seizures: First interim analysis

Patients with epilepsy often take more than one medication for seizure control. This 12month study looked at patients in Germany receiving perampanel as only add-on medication. The interim analysis shows, that at 6 months, over 70% of the 100 patients continued to use perampanel; 59% experienced no seizures during treatment with perampanel, and in 83%, seizure frequency was reduced by half. Side effects occurred in 48% of patients (most commonly dizziness, fatigue, and irritability) and caused 16% to withdraw from the study. Overall, perampanel was a suitable as only add-on medication for patients with epilepsy.